Our most advanced product candidate, NasoVAX™, an intranasally administered recombinant influenza vaccine, uses an adenovector to achieve expression of the influenza antigen in the target cell, thereby potentially stimulating a broader and more rapid immune response than traditional influenza vaccines. Our second most advanced product candidate, HepTcell™, is being tested as an immunotherapy for patients chronically infected with the hepatitis B virus, or HBV, and has the potential to provide a functional cure, something that is not achievable with current treatments. SparVax-L is being developed in cooperation with the National Institute of Allergy and Infectious Diseases as a second-generation anthrax vaccine that will require only two doses for protection instead of the three-dose regimen required by the currently approved product. Additionally, with the support of the U.S. Biomedical Advanced Research and Development Authority, or BARDA, we are developing a fourth product candidate, NasoShield™, a first-in-class anthrax vaccine designed to provide rapid, stable protection after a single intranasal administration. We also have a preclinical program, Oncosyn™, for developing immunotherapeutic product candidates against cancer. Oncosyn can be combined with immune checkpoint inhibitors for improved antitumor activity.